Top Page
Zai Lab Ltd
(Frankfurt:9688)
Zai Lab Ltd (9688) vs. iShares MSCI Hong Kong ETF (EWH)
Zai Lab Ltd Business Overview & Revenue Model
Zai Lab Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 427.80M | 398.99M | 266.72M | 215.04M | 144.31M | 48.96M |
| Gross Profit | 266.92M | 251.13M | 170.90M | 141.02M | 92.07M | 32.22M |
| EBITDA | -195.33M | -242.99M | -365.11M | -384.66M | -689.46M | -262.96M |
| Net Income | -212.52M | -257.10M | -334.62M | -481.99M | -692.44M | -298.16M |
Balance Sheet | ||||||
| Total Assets | 1.16B | 1.19B | 1.04B | 1.22B | 1.61B | 1.30B |
| Cash, Cash Equivalents and Short-Term Investments | 732.16M | 779.67M | 806.45M | 1.01B | 1.41B | 1.19B |
| Total Debt | 191.40M | 153.47M | 15.15M | 20.39M | 15.54M | 18.60M |
| Total Liabilities | 372.37M | 344.86M | 240.18M | 174.54M | 230.00M | 128.29M |
| Stockholders Equity | 791.74M | 840.90M | 796.12M | 1.05B | 1.38B | 1.17B |
Cash Flow | ||||||
| Free Cash Flow | -230.99M | -276.39M | -206.67M | -392.63M | -568.18M | -226.72M |
| Operating Cash Flow | -175.31M | -214.87M | -198.18M | -367.64M | -549.23M | -216.06M |
| Investing Cash Flow | -54.43M | -375.19M | -10.78M | 420.02M | 249.96M | -554.83M |
| Financing Cash Flow | 332.01M | 349.89M | -6.43M | -1.73M | 820.20M | 1.13B |
Zai Lab Ltd Technical Analysis
Zai Lab Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$34.13B | 38.35 | 27.37% | ― | 2.57% | 18.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$10.93B | 42.78 | 13.34% | ― | 206.58% | ― | |
43 Neutral | HK$39.44B | -25.46 | -15.06% | ― | 39.02% | 48.26% | |
41 Neutral | HK$23.00B | ― | -29.51% | ― | 32.07% | 33.55% | |
40 Underperform | HK$56.01B | -48.21 | -39.64% | ― | 46.14% | 39.56% | |
39 Underperform | HK$11.75B | -56.13 | -21.42% | ― | 240.05% | -140.09% |
Zai Lab Ltd Corporate Events
Zai Lab Limited announced that its Audit Committee will review and approve the company’s unaudited quarterly results for the third quarter of 2025 on November 6, 2025. Following the approval, the company plans to publish the results and hold a live earnings teleconference to discuss the outcomes, indicating a proactive approach to transparency and stakeholder engagement.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Ltd has adopted a new charter for its Nominating and Corporate Governance Committee, which outlines the committee’s purpose, composition, procedures, and responsibilities. This move is aimed at enhancing corporate governance and ensuring the selection of qualified individuals for the board, thereby strengthening the company’s leadership and aligning with Nasdaq and Hong Kong Stock Exchange standards.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Limited announced the grant of share options and restricted share units under its 2024 Equity Incentive Plan. The company granted options to subscribe for 25,000 American Depositary Shares (ADSs) to one employee and 32,150 restricted share units to seven employees. These grants are part of the company’s strategy to align employee incentives with its long-term goals, although they do not include performance targets or clawback mechanisms. The move is seen as market competitive and consistent with Zai Lab’s customary practices, potentially impacting employee retention and motivation positively.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$27.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Limited announced the grant of share options and restricted share units under its 2024 Equity Incentive Plan. On September 8, 2025, the company granted options to subscribe for 6,600 American Depositary Shares (ADSs) to two employees and 9,893 restricted share units to four employees. These grants are part of the company’s strategy to align employee incentives with its long-term goals, although they do not include performance targets or clawback mechanisms. The move is seen as market competitive and consistent with the company’s customary practices.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Limited announced an update on the Phase 3 FORTITUDE-101 study, conducted in partnership with Amgen, evaluating bemarituzumab combined with chemotherapy for first-line gastric cancer. While the interim analysis showed significant improvement in overall survival, the final analysis indicated a reduced benefit. The company plans to await results from the FORTITUDE-102 study before proceeding with regulatory filings, with data expected by late 2025 or early 2026.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$27.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Limited announced its unaudited interim results for the six months ending June 30, 2025, showing a 15% increase in net product revenue to $214.7 million, driven by higher sales of key products. The company also reported a decrease in net loss by 33% to $89.2 million, attributed to revenue growth outpacing operating expenses, alongside reduced research and development, and administrative costs due to resource prioritization and efficiency efforts.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$27.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Ltd announced the grant of 3,300 Restricted Share Units (RSUs) to three employees under its 2024 Equity Incentive Plan. This move is intended to recognize and reward the contributions of these employees and to provide additional incentives for their continued success with the company. The RSUs will vest over four years, with no performance targets or clawback mechanisms attached, aligning with the company’s market-competitive practices. This grant reflects Zai Lab’s commitment to fostering employee engagement and promoting business success.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Limited announced that its Audit Committee will review and approve the unaudited condensed consolidated results for the six months ended June 30, 2025. These results, previously filed with the SEC, will be published in compliance with the Hong Kong Stock Exchange’s listing rules, including additional disclosures and a reconciliation from U.S. GAAP to IFRS. This action underscores Zai Lab’s commitment to transparency and adherence to international financial reporting standards, which may enhance investor confidence and align with global market practices.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Limited announced its unaudited financial results for the second quarter of 2025, reporting a 9% year-over-year increase in total revenues to $110 million. The company highlighted significant progress in its product pipeline, including record patient utilization of VYVGART and promising data for ZL-1310 in SCLC and bemarituzumab in gastric cancer. With a 28% reduction in operating loss and expectations of achieving profitability by the fourth quarter, Zai Lab is poised for growth with multiple high-impact product launches and a robust pipeline.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Limited announced the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, with the U.S. Securities and Exchange Commission. This regulatory filing is significant for stakeholders as it provides detailed insights into the company’s financial performance and operational status, which can impact its market positioning and investor confidence.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.